VCRE (Vicore Pharma Holding AB) stock: $10.55, $2.97B market cap, $39.6M cash, $2.93B EV. Lead program: Buloxibutid (Idiopathic Pulmonary Fibrosis (IPF)), Phase 2. Data from Fully Diluted's biotech stocks database.
What they do
Vicore Pharma is a clinical-stage biopharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists, a new class of drugs with disease-modifying potential in respiratory and fibrotic diseases, with lead program buloxibutid in the Phase 2b ASPIRE trial in idiopathic pulmonary fibrosis.
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 0 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.